Literature DB >> 20730608

B lymphoblastic lymphoma presenting as a tumor of the nasopharynx in an adult patient.

Rodrigo Lopes da Silva1, Teresa Fernandes, Alexandra Lopes, Susana Santos, Manuela Mafra, António Silva Rodrigues, Aida Botelho de Sousa.   

Abstract

In adults, non-Hodgkin's lymphoma (NHL) is the second most common neoplasm found in the head and neck region after squamous cell carcinoma. Within this region, primary NHL of the nasopharynx is rare. We report the case of a 28-year-old male diagnosed with a B lymphoblastic lymphoma (CD20-; CD79a+; CD3-; CD10+; PAX5+, CyclinD1-; TdT+) of the nasopharynx extending to the deep and superficial structures of the right hemiface, to the skull base with an intracranial component and a small but detectable bone marrow involvement, who was started on chemotherapy with a complete response. To the best of our knowledge, this is the first case of a primary nasopharynx B-LBL in an adult patient with such aggressive regional spread to be reported in the literature.

Entities:  

Mesh:

Year:  2010        PMID: 20730608      PMCID: PMC2996508          DOI: 10.1007/s12105-010-0206-2

Source DB:  PubMed          Journal:  Head Neck Pathol        ISSN: 1936-055X


  28 in total

1.  Waldeyer's ring lymphomas: a clinical study from the Comprehensive Cancer Center West population based NHL registry.

Authors:  A D Krol; S Le Cessie; S Snijder; J C Kluin-Nelemans; P M Kluin; E M Noorduk
Journal:  Leuk Lymphoma       Date:  2001 Sep-Oct

2.  Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.

Authors:  H M Kantarjian; S O'Brien; T L Smith; J Cortes; F J Giles; M Beran; S Pierce; Y Huh; M Andreeff; C Koller; C S Ha; M J Keating; S Murphy; E J Freireich
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

3.  [Clinical features, treatment and prognosis of 136 patients with primary non-Hodgkin's lymphoma of the nasopharynx].

Authors:  Zhi-yong Yuan; Ye-xiong Li; Lu-jun Zhao; Yuan-hong Gao; Xin-fan Liu; Da-zhong Gu; Tu-nan Qian; Zi-hao Yu
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2004-07

Review 4.  [Relapse of acute lymphoblastic leukemia as a retro-orbital mass].

Authors:  H Kajimoto; M Naya; M Hojo; S Hibi; S Imashuku
Journal:  Rinsho Ketsueki       Date:  1999-11

5.  Localized non-Hodgkin's lymphoma of Waldeyer's ring: clinical features, management, and prognosis of 130 adult patients.

Authors:  A A Ezzat; E M Ibrahim; A N El Weshi; Y M Khafaga; M AlJurf; J M Martin; D S Ajarim; S N Bazarbashi; R K Stuart; E Zucca
Journal:  Head Neck       Date:  2001-07       Impact factor: 3.147

Review 6.  Precursor B-cell lymphoblastic lymphoma. A study of nine cases lacking blood and bone marrow involvement and review of the literature.

Authors:  A Maitra; R W McKenna; A G Weinberg; N R Schneider; S H Kroft
Journal:  Am J Clin Pathol       Date:  2001-06       Impact factor: 2.493

7.  Precursor B-cell lymphoblastic lymphoma: a predominantly extranodal tumor with low propensity for leukemic involvement.

Authors:  P Lin; D Jones; D M Dorfman; L J Medeiros
Journal:  Am J Surg Pathol       Date:  2000-11       Impact factor: 6.394

8.  Prognostic factors and therapeutic efficacy of combined radio-chemotherapy in Waldeyer's ring non-Hodgkin lymphoma.

Authors:  W Yong; Y Zhang; W Zheng; Y Wei
Journal:  Chin Med J (Engl)       Date:  2000-02       Impact factor: 2.628

9.  Adult lymphoblastic lymphoma: a retrospective analysis of 92 patients under 61 years included in the LNH87/93 trials.

Authors:  S Le Gouill; S Lepretre; J Brière; P Morel; R Bouabdallah; E Raffoux; C Sebban; E Lepage; P Brice
Journal:  Leukemia       Date:  2003-11       Impact factor: 11.528

10.  Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma.

Authors:  Deborah A Thomas; Susan O'Brien; Jorge Cortes; Francis J Giles; Stefan Faderl; Srdan Verstovsek; Alessandra Ferrajoli; Charles Koller; Miloslav Beran; Sherry Pierce; Chul S Ha; Fernando Cabanillas; Michael J Keating; Hagop Kantarjian
Journal:  Blood       Date:  2004-06-03       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.